Loading…
Lack of association between prior depressive episodes and cerebral [11 C]PiB binding
Abstract Depressive symptoms are frequent in Alzheimer's disease (AD), but it is controversial whether depression is a risk factor for AD. This study measured for the first time cortical amyloid-β (Aβ) levels using [11 C] Pittsburgh Compound B (PiB) positron emission tomography (PET) in a group...
Saved in:
Published in: | Neurobiology of aging 2012-10, Vol.33 (10), p.2334-2342 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Abstract Depressive symptoms are frequent in Alzheimer's disease (AD), but it is controversial whether depression is a risk factor for AD. This study measured for the first time cortical amyloid-β (Aβ) levels using [11 C] Pittsburgh Compound B (PiB) positron emission tomography (PET) in a group of nondemented patients with prior depressive episodes. Twenty-eight elderly patients (mean age 61 years, range 51–75, 18 women) with onset of first depressive episode more than 6 years ago but now remitted from depression and 18 healthy subjects (mean age 61 years, range 50–76, 12 women) were included. All subjects were investigated with cognitive testing, 3T magnetic resonance imaging (MRI) and [11 C]PiB high resolution research tomography (HRRT) positron emission tomography scan. There was no between-groups difference in [11 C]PiB binding ( p = 0.5) and no associations to number of depressive episodes, cognitive performance, or antidepressant treatment. Patients with late onset of depression had increased severity of white matter lesions ( p = 0.04). In this study depressive episodes were not associated with increased levels of [11 C]PiB. Thus, our results do not support the notion that depressive episodes previously in life are a risk factor for developing AD. |
---|---|
ISSN: | 0197-4580 1558-1497 |
DOI: | 10.1016/j.neurobiolaging.2011.11.021 |